Defeating malaria together

Delivery of child-friendly antimalarial hits the 100 million mark

One hundred million treatments of Artemether-Lumefantrine Dispersible, an antimalarial developed especially for children with P. falciparum malaria, have been delivered by Novartis to 35 malaria-endemic countries. Artemether-Lumefantrine Dispersible is the product of the partnership between MMV and Novartis. It is the first WHO prequalified child-friendly artemisinin-combination therapy (ACT) and addresses an unmet need for paediatric medicines.

This film, produced by Novartis, accompanies the press release Delivery of child-friendly antimalarial hits the 100 million mark, posted 22 February 2012.

February 2012

 

Array ( [0] => front_not [1] => site_english [2] => view_rhs-column [3] => force_sidebars [4] => node_landing-pages_not [5] => node_video [6] => share [7] => submenu [8] => view_related [9] => view_rhs-column-below [10] => breadcrumb [11] => internal_adverts_desktop [12] => sitewide_desktop [13] => superfish_menu_desktop )